Amphastar Pharmaceuticals (AMPH) Research & Development (2013 - 2026)

Amphastar Pharmaceuticals' Research & Development history runs 14 years deep, the most recent figure standing at $26.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 33.05% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $92.5 million (up 20.16% YoY), while the FY2025 annual figure was $85.8 million, up 16.14% from the prior year.
• Research & Development was $26.7 million for Q1 2026 at Amphastar Pharmaceuticals, up from $23.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $26.7 million in Q1 2026 to a low of $16.2 million in Q1 2022.
• Historically, Research & Development has averaged $19.7 million across 5 years, with a median of $19.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 72.08% in 2022, then dropped 26.12% in 2023.
• A 5-year view of Research & Development shows it stood at $17.2 million in 2022, then gained by 18.47% to $20.4 million in 2023, then dropped by 11.15% to $18.1 million in 2024, then gained by 28.51% to $23.3 million in 2025, then gained by 14.68% to $26.7 million in 2026.
• The last three Research & Development figures came in at $26.7 million (Q1 2026), $23.3 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.